OA11230A - Benzimidazole derivatives - Google Patents

Benzimidazole derivatives Download PDF

Info

Publication number
OA11230A
OA11230A OA9900275A OA9900275A OA11230A OA 11230 A OA11230 A OA 11230A OA 9900275 A OA9900275 A OA 9900275A OA 9900275 A OA9900275 A OA 9900275A OA 11230 A OA11230 A OA 11230A
Authority
OA
OAPI
Prior art keywords
hydrogen
benzimidazole
galkyl
bromo
halogen
Prior art date
Application number
OA9900275A
Other languages
English (en)
Inventor
John Charles Drach
Leroy B Townsend
Boyd Frank Leslie Jr
Stanley Dawes Chamberlain
Susan Mary Daluge
David Norman Deaton
Marc W Andersen
Freeman George Andrew
Original Assignee
Glaxo Group Ltd
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9711982.0A external-priority patent/GB9711982D0/en
Priority claimed from GBGB9714552.8A external-priority patent/GB9714552D0/en
Application filed by Glaxo Group Ltd, Univ Michigan filed Critical Glaxo Group Ltd
Publication of OA11230A publication Critical patent/OA11230A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA9900275A 1997-06-10 1999-12-09 Benzimidazole derivatives OA11230A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711982.0A GB9711982D0 (en) 1997-06-10 1997-06-10 Benzimidazole derivatives
GBGB9714552.8A GB9714552D0 (en) 1997-07-11 1997-07-11 Benzimidazole derivatives

Publications (1)

Publication Number Publication Date
OA11230A true OA11230A (en) 2003-07-09

Family

ID=26311687

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900275A OA11230A (en) 1997-06-10 1999-12-09 Benzimidazole derivatives

Country Status (35)

Country Link
US (1) US6455507B1 (no)
EP (1) EP0994890B1 (no)
JP (1) JP4548866B2 (no)
KR (1) KR20010020465A (no)
CN (1) CN1265665A (no)
AP (1) AP1262A (no)
AR (1) AR012964A1 (no)
AT (1) ATE246700T1 (no)
AU (1) AU740792C (no)
BR (1) BR9810745A (no)
CA (1) CA2293470C (no)
CO (1) CO4970737A1 (no)
DE (1) DE69816992T2 (no)
DK (1) DK0994890T3 (no)
EA (1) EA002305B1 (no)
EE (1) EE9900564A (no)
ES (1) ES2205527T3 (no)
HK (1) HK1024921A1 (no)
HR (1) HRP980303B1 (no)
HU (1) HUP0002224A3 (no)
ID (1) ID24054A (no)
IL (1) IL133285A0 (no)
IS (1) IS5285A (no)
MA (1) MA26504A1 (no)
MY (1) MY132872A (no)
NO (1) NO314847B1 (no)
NZ (1) NZ501415A (no)
OA (1) OA11230A (no)
PE (1) PE84099A1 (no)
PL (1) PL337773A1 (no)
PT (1) PT994890E (no)
SK (1) SK171499A3 (no)
TR (1) TR199903053T2 (no)
TW (1) TW565566B (no)
WO (1) WO1998056761A2 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9707185A (pt) 1996-01-23 1999-03-23 Glaxo Group Ltd Nucleosídeos de benzimidazol modificados como agentes antivirais
NZ502882A (en) 1997-07-30 2002-02-01 Glaxo Group Ltd Lyxofuranosyl benzimidazoles as antiviral agents
DE19741715A1 (de) * 1997-09-22 1999-03-25 Hoechst Ag Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
GB0008939D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
WO2002072090A1 (en) 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2004261663A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
WO2005049582A1 (en) * 2003-11-14 2005-06-02 Auspex Pharmaceuticals, Inc. Method of preparation of novel nucleoside analogs and uses
CN101160314B (zh) * 2005-02-22 2012-05-23 密执安州立大学董事会 Mdm2的小分子抑制剂以及其应用
DE102005019549A1 (de) * 2005-04-25 2006-12-14 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Diaminobenzimidazol
EP2545923A1 (en) * 2005-12-22 2013-01-16 Alchemia Limited Antibacterial agents
US8338397B2 (en) 2006-01-19 2012-12-25 The Regents Of The University Of Michigan Composition and method of treating side effects from antibiotic treatment
US10238599B2 (en) 2006-01-19 2019-03-26 The Regents Of The University Of Michigan Composition and method for treating congenital cytomegalovirus induced hearing loss
US9889156B2 (en) 2006-01-19 2018-02-13 The Regents Of The University Of Michigan Method for treating noise-induced hearing loss (NIHL)
US9770433B2 (en) 2006-01-19 2017-09-26 The Regents Of The University Of Michigan Composition and method for treating tinnitus
US8927528B2 (en) 2006-01-19 2015-01-06 The Regents Of The University Of Michigan Composition for treating hearing loss
US9919008B2 (en) 2006-01-19 2018-03-20 The Regents Of The University Of Michigan Method for treating age-related hearing loss (ARHL)
US7951845B2 (en) 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
USRE46372E1 (en) 2006-01-19 2017-04-25 The Regents Of The Univerity Of Michigan Method for treating hearing loss
AU2008286771B2 (en) 2007-08-15 2013-08-15 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US8987468B2 (en) * 2008-02-04 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US8394969B2 (en) 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2011004505A (es) 2008-10-29 2011-05-31 Merck Sharp & Dohme Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US20120021515A1 (en) 2009-02-06 2012-01-26 Swayze Eric E Oligomeric compounds and methods
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8993738B2 (en) 2010-04-28 2015-03-31 Isis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
US8546344B2 (en) 2010-10-28 2013-10-01 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl)-1H-benzimidazole
WO2014134493A1 (en) * 2013-03-01 2014-09-04 Los Alamos National Security, Llc Broad spectrum antibiotic compounds and use thereof
DK3137476T3 (da) 2014-04-28 2019-11-18 Ionis Pharmaceuticals Inc Linker-modificerede oligomerforbindelser
US10077242B2 (en) * 2014-12-01 2018-09-18 Virginia Commonwealth University Convergent approach to the total synthesis of telmisartan via a suzuki cross-coupling reaction
RU2629670C2 (ru) * 2016-08-04 2017-08-31 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) 2-Амино-5,6-дифтор-1-(бета-D-рибофуранозил)-бензимидазол, способ получения и противовирусная активность его в отношении вируса герпеса простого 1-го типа
EP3907230B1 (en) * 2020-03-30 2024-08-28 Biometrix Technology Inc. Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same
KR102583547B1 (ko) 2020-03-30 2023-10-06 (주)바이오메트릭스 테크놀로지 신규한 벤지미다졸 유도체, 이의 제조방법 및 이의 항암제 용도
EP4169930A4 (en) * 2020-06-23 2024-07-24 Biometrix Tech Inc NOVEL BENZIMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND ITS USE AS AN ANTI-CANCER AGENT OR ANTIVIRAL AGENT
KR102449266B1 (ko) 2020-06-23 2022-09-30 (주)바이오메트릭스 테크놀로지 항암 활성 그리고 항바이러스 활성을 갖는 신규한 벤지미다졸-탄수화물 결합체 화합물(Benzimidazole carbohydrate conjugate compound) 및 이의 제조 방법
KR102342313B1 (ko) 2021-08-27 2021-12-24 (주)바이오메트릭스 테크놀로지 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1491244A (fr) 1966-03-09 1967-08-11 Nouveaux benzimidazoles solubles
FR1476350A (fr) 1966-04-18 1967-04-07 Yale & Towne G M B H Ferme-porte automatique à frein
US3655901A (en) 1970-07-30 1972-04-11 Merck & Co Inc Method of inhibiting the formation of phenylethanalamine-n-methyl transferase with 2-aminobenzimidazoles
DE2130030A1 (de) 1971-06-18 1972-12-21 Bayer Ag Fungizide und bakterizide Mittel
ES8101067A1 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
EP0304624A3 (de) 1987-07-29 1989-03-22 F. Hoffmann-La Roche Ag Benzimidazol-2-yl-pyridiniumverbindungen
IT1226100B (it) 1988-07-07 1990-12-10 Dompe Farmaceutici Spa Derivati benzimidazolici farmacologicamente attivi.
US5248672A (en) * 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
EP0521463A3 (en) 1991-07-04 1993-04-14 Hoechst Aktiengesellschaft Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
GB9205071D0 (en) 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
AU5447094A (en) 1992-10-21 1994-05-09 Regents Of The University Of Michigan, The Polysubstituted benzimidazoles as antiviral agents
US5399580A (en) 1993-03-08 1995-03-21 Burroughs Wellcome Co. Therapeutic nucleosides-uses
GB9413724D0 (en) 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides

Also Published As

Publication number Publication date
AP1262A (en) 2004-03-16
AU740792C (en) 2003-01-23
EE9900564A (et) 2000-06-15
CN1265665A (zh) 2000-09-06
HRP980303A2 (en) 1999-04-30
CA2293470C (en) 2008-05-13
DK0994890T3 (da) 2003-12-01
WO1998056761A2 (en) 1998-12-17
AR012964A1 (es) 2000-11-22
EP0994890B1 (en) 2003-08-06
KR20010020465A (ko) 2001-03-15
US20020094963A1 (en) 2002-07-18
JP2002504105A (ja) 2002-02-05
ES2205527T3 (es) 2004-05-01
SK171499A3 (en) 2000-08-14
WO1998056761A3 (en) 1999-04-15
MY132872A (en) 2007-10-31
HK1024921A1 (en) 2000-10-27
HUP0002224A1 (hu) 2001-04-28
PT994890E (pt) 2003-11-28
BR9810745A (pt) 2001-03-13
EP0994890A2 (en) 2000-04-26
TW565566B (en) 2003-12-11
MA26504A1 (fr) 2004-12-20
DE69816992T2 (de) 2004-07-22
IL133285A0 (en) 2001-04-30
ID24054A (id) 2000-07-06
AP9901707A0 (en) 1999-12-31
AU740792B2 (en) 2001-11-15
DE69816992D1 (en) 2003-09-11
HRP980303B1 (en) 2002-08-31
NO996086L (no) 2000-02-09
NO314847B1 (no) 2003-06-02
NO996086D0 (no) 1999-12-09
PL337773A1 (en) 2000-09-11
CA2293470A1 (en) 1998-12-17
ATE246700T1 (de) 2003-08-15
US6455507B1 (en) 2002-09-24
JP4548866B2 (ja) 2010-09-22
IS5285A (is) 1999-12-06
CO4970737A1 (es) 2000-11-07
EA199901031A1 (ru) 2000-06-26
EA002305B1 (ru) 2002-02-28
HUP0002224A3 (en) 2003-05-28
TR199903053T2 (xx) 2000-11-21
NZ501415A (en) 2001-10-26
AU8536098A (en) 1998-12-30
PE84099A1 (es) 1999-09-24

Similar Documents

Publication Publication Date Title
OA11230A (en) Benzimidazole derivatives
AU702248B2 (en) Therapeutic compounds
KR20020020788A (ko) 벤즈이미다졸론 유도체 및 포스포디에스테라제억제제로서의 이의 용도
AU729541B2 (en) Therapeutic compounds
EP0970100B1 (en) Benzimidazole derivatives
MXPA99011562A (en) Benzimidazole derivatives
CZ448299A3 (cs) Benzimidazolové deriváty, způsob jejich výroby, farmaceutický prostředek obsahující tyto deriváty a použití těchto derivátů